Clinical characteristics and survival of BRAF-mutant (BRAF+) metastatic melanoma patients (pts) treated with BRAF inhibitor (BRAFi) dabrafenib or vemurafenib beyond disease progression (PD).
Matthew Chan
No relevant relationships to disclose
Lauren Haydu
No relevant relationships to disclose
Alexander M. Menzies
Other Remuneration - GlaxoSmithKline; Roche
Mary W. F. Azer
No relevant relationships to disclose
Oliver Klein
No relevant relationships to disclose
Alexander Guminski
Honoraria - Roche
Richard Kefford
Consultant or Advisory Role - GlaxoSmithKline; Roche
Georgina Long
Consultant or Advisory Role - GlaxoSmithKline; Novartis; Roche
Honoraria - Roche